Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$2.90
EPS est.
$2.77
EPS surprise
+4.73%
1-day move
+5.87%
Becton, Dickinson's earnings report showed a positive surprise in EPS, which likely contributed to the stock's 5.87% increase. Investors may view the EPS beat as a sign of strong performance, even though revenue details were not disclosed. The lack of guidance may leave some investors cautious about future expectations.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.90 | $2.78 | +4.73% |
| Revenue | — | $4.7B | — |
No transcript is on record, and the analysis is based on numerical results only.
Becton, Dickinson and Company (BDX) is a leading global medical technology company that develops and manufactures a wide range of medical devices, instrument systems, and reagents. As a key player in the health care sector, BDX's products are essential for hospitals and laboratories, especially in areas like diagnostics, medication management, and infection prevention.
Last quarter
In Q1-2026, BDX reported an EPS of $2.91, exceeding analyst expectations by 3.34%. However, the stock fell by 1.25% the following day, indicating mixed investor sentiment despite the earnings beat.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+4.62%
Avg 1-day reaction
-0.58%
Analysts are generally optimistic about BDX's upcoming earnings, expecting a solid EPS of $2.78 and revenue of $4.7B. The company has a strong track record of beating earnings estimates, which could influence market reactions.
Bull case
If BDX continues its trend of exceeding earnings expectations, it could lead to a positive market reaction, especially if management provides strong guidance for future growth.
Bear case
Conversely, if the company fails to meet expectations or provides cautious guidance, it could lead to a significant drop in stock price, especially given the recent mixed reactions to earnings beats.
Key metrics to watch
EPS
$2.78Earnings per share is a critical measure of profitability and will indicate how well the company is managing costs and generating profit.
Revenue
$4.7BRevenue growth is vital for assessing the company's market demand and overall business health.
The print will turn on these.
Q1
Will BDX's EPS exceed the consensus estimate of $2.78?
A beat on EPS could reinforce investor confidence and lead to a positive stock reaction, given the company's history of surpassing earnings expectations.
Q2
What guidance will management provide regarding revenue growth?
Investors will closely watch for any indications of future revenue performance, as this could significantly impact stock sentiment.
—
Est. EPS
$0.14
Est. Rev
$2.4B
Impl. Move
±9.5%
Why consensus could be wrong
The consensus may underestimate BDX's ability to leverage recent innovations in medical technology, which could drive higher-than-expected revenue growth.
Supporting evidence
BDX has consistently beaten EPS estimates in the past, indicating strong operational performance.
Recent trends in health care spending suggest increased demand for BDX's products, which may not be fully reflected in current estimates.
Key risk
If BDX's revenue growth exceeds expectations due to strong demand, it could significantly alter market perceptions.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will test the company's ability to maintain growth amidst market challenges.
Bull confirmed if
An EPS of $2.80 or higher, coupled with positive revenue growth guidance, would confirm the bull case.
Bear confirmed if
An EPS below $2.76 or disappointing revenue guidance would confirm the bear case.
What the market is pricing for the move.
Implied Move
±6.5%
Historical Avg
±5.6%
The options market is pricing in a potential move of about 6.5% in either direction following the earnings report, suggesting that traders expect volatility.
Options are pricing ±7.7% while BDX has averaged ±5.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
20.2%
Smart-money positioning from the most recent 13F filings.
Institutional
99.78%
of float
Insider
0.43%
of float
Holders
1,920
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
24,592,166 sh · $4.4B
8.93%
-6.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If BDX beats expectations, history suggests a potential stock increase of around 1.69%, confirming the company's strong performance.
In line / cautious
If results are in line with expectations but management provides cautious commentary, the stock may react neutrally, reflecting uncertainty.
Miss
A miss could lead to a decline, with historical patterns indicating a potential drop of around 1.69%.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Vanguard Capital Management LLC
17,987,834 sh · $3.2B
6.53%
-2.7%
State Street Corporation
15,000,064 sh · $2.7B
5.44%
8.5%
Vanguard Portfolio Management LLC
14,974,136 sh · $2.7B
5.43%
-2.2%
First Eagle Investment Management, LLC
13,815,335 sh · $2.5B
5.01%
15.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded May 21, 2026 · disclosed Jun 18, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.